Christina N Carrigan

This inventor holds 11 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignee: Immunogen, Inc.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christina N Carrigan. Retrieved from https://idiyas.com/inventor/christina-n-carrigan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 110(Granted Patents)

Location History:

Belmont, MA (US) (2014 - 2021)
San Francisco, CA (US) (2020 - 2024)

Company Filing History:

11 out of 256

Immunogen, Inc.

patents

Years Active: 2014-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11932701 - Method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugate (2024-03-19),

2. 11198736 - Method for identifying an ovarian cancer in a subject likely to respond to anti-folate receptor 1 (FOLR1) antibody (2021-12-14),

3. 11135305 - Methods for increasing efficacy of FOLR1 cancer therapy (2021-10-05),

4. 10613093 - Diagnostic assays and kits for detection of folate receptor 1 (2020-04-07),

5. 10544230 - Methods of using antibodies to detect folate receptor 1 (FOLR1) (2020-01-28),

6. 10180432 - Diagnostic assays and kits for detection of folate receptor 1 (2019-01-15),

7. 10017578 - Methods of treating cancer in a patient by administering anti-folate-receptor-1 (FOLR1) antibodies (2018-07-10),

8. 9702881 - Diagnostic assays and kits for detection of folate receptor 1 (2017-07-11),

9. 9637547 - Monoclonal antibodies for detection of folate receptor 1 (2017-05-02),

10. 9200073 - Diagnostic assays and kits for detection of folate receptor 1 (2015-12-01),

11. 8709432 - Methods for increasing efficacy of FOLR1 cancer therapy (2014-04-29),

Title: Christina N Carrigan: Innovator in Cancer Therapy

Introduction

Christina N Carrigan is a prominent inventor based in Belmont, MA (US), known for her significant contributions to cancer therapy. With a total of 11 patents to her name, she has made remarkable strides in the field of immunology and oncology.

Latest Patents

Among her latest patents is a method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugate. This invention relates to antibodies that bind to the human folate receptor and includes diagnostic assays for folate receptor 1-based therapies. Additionally, she has developed a method for identifying ovarian cancer in a subject likely to respond to anti-folate receptor 1 (FOLR1) antibody. This invention also focuses on antibodies that bind to the human folate receptor and provides methods for monitoring therapy.

Career Highlights

Christina works at Immunogen, Inc., where she continues to innovate and develop new therapeutic strategies. Her work has been instrumental in advancing the understanding and treatment of cancers that express the folate receptor.

Collaborations

Some of her notable coworkers include Olga Ab and Daniel J Tavares, who contribute to her research and development efforts.

Conclusion

Christina N Carrigan's work exemplifies the impact of innovative thinking in the medical field, particularly in cancer therapy. Her patents and ongoing research are paving the way for more effective treatments and improved patient outcomes.

Profile summary based on public USPTO records.